NCT07024277View on ClinicalTrials.gov

Study of ZG006 in Participants With Neuroendocrine Prostate Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

August 31, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
Neuroendocrine Prostate Cancer
Interventions
BIOLOGICAL

ZG006

ZG006 will be administered as an intravenous (IV) infusion.

Trial Locations (1)

Unknown

Fudan university shanghai cancer center, Shanghai

All Listed Sponsors
lead

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

INDUSTRY